CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 124 enrolled
Drug / intervention
Norfloxacin +1 moredrug
Likely dose
Norfloxacin 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01542801
NCT01542801Phase 4Completed

Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients

Korea University·interventional·Posted Mar 2, 2012·Updated Dec 28, 2016

In Brief

A Phase 4 clinical trial evaluating Norfloxacin and ciprofloxacin for Adverse Reaction to Other Drugs and Medicines. Completed, enrolled 124 participants across 7 sites.

Detailed Summary

* For the prevention of spontaneous bacterial peritonitis (SBP) in patients with liver cirrhosis, norfloxacin 400mg per day is a standard regimen. * Ciprofloxacin 750 mg per week is also known to be effective for prevention of SBP. In addition, ciprofloxacin once weekly administration is more convenient and less costly. * Therefore ciprofloxacin once weekly could be more useful if the the efficacy is comparable to norfloxacin once daily. * This study aims to prove ciprofloxacin once weekly administration is as effective as norfloxacin once daily administration for the prevention of SBP in cirrhotic patients with ascites.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2, 2012
Enrollment StartAug 1, 2011
Primary CompletionJul 1, 2015
Study CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 14.3 years ago

Interventions

Norfloxacindrug

Norfloxacin 400 mg per day

ciprofloxacindrug

Ciprofloxacin 750 mg per week